New Spravato Indication Offers Greater Flexibility and Personalization for Patients with Treatment-Resistant Depression

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression.